Hims & Hers Health, Inc. (HIMS) announced Wednesday it's acquiring YourBio Health, Inc., a Boston-based company that's figured out how to make blood tests a lot less unpleasant.

YourBio specializes in capillary whole blood sampling technology that reimagines when, where, and how blood samples can be collected. The idea is to move blood testing beyond traditional clinic settings and into people's homes.

The star of the show is YourBio's TAP device, which runs on something called HALO technology. Instead of the usual fingerstick or venipuncture needle that makes you wince, it uses bladeless microneedles thinner than an eyelash. The result? High-quality capillary blood samples collected in seconds, without the pain or hassle of conventional methods.

"YourBio's HALO and TAP technologies are ushering in some of the most significant scientific advancements in the blood collection space in decades," said Michael Mina, Chief Scientific Officer at YourBio Health. "By using micro-needles thinner than an eyelash, these systems produce high-quality blood samples with essentially no discomfort."

The acquisition brings this pain-free blood sampling tech directly into Hims & Hers' portfolio. Along with the technology, Hims & Hers is also bringing on YourBio's Michael Mina and Paul Owen to join the team.

The deal is structured as an all-cash transaction funded from Hims & Hers' balance sheet, with closing expected in early 2026.

This move fits neatly into Hims & Hers' recent expansion into comprehensive health monitoring. Last November, the company launched Labs, a service that tracks key health markers over time and delivers doctor-developed action plans. Labs gives customers insights into heart health, metabolism, hormones, inflammation, and stress management.

With YourBio's technology in hand, Hims & Hers can make that monitoring process significantly more convenient and comfortable for users.

Price Action: HIMS stock was down 0.97% at $35.96 on Wednesday.